Tag: TopLine

Posted on

ALK announces top-line results from the five-year landmark GRAZAX® Asthma … – GlobeNewswire (press release)

ALK announces top-line results from the five-year landmark GRAZAX® Asthma …
GlobeNewswire (press release)
The trial did not show an effect in terms of time to first diagnosis of reversible impairment of lung function. The trial demonstrated that GRAZAX® treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma …
BRIEF-Alk Abello announces results from GRAZAX Asthma Prevention trial in childrenReuters
ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma …EconoTimes

all 6 news articles »

View full post on asthma – Google News

Posted on

ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma … – EconoTimes

ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma …
EconoTimes
In contrast, treatment with GRAZAX(r) had a positive effect on the children's asthma symptoms and use of asthma medication. The odds ratio (secondary endpoint) for experiencing asthma symptoms[1] or using asthma medication[2], at the end of the five …

and more »

View full post on asthma – Google News

Posted on

Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987 – NASDAQ

Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ
(RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data …
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of …MarketWatch (press release)
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 StudyBenzinga

all 9 news articles »

View full post on asthma – Google News

Posted on

Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987 – RTT News

Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987
RTT News
(RTTNews) – Targacept Inc. (TRGT: News ) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the US, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met …
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of …MarketWatch (press release)

all 6 news articles »

View full post on asthma – Google News